PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q85464

YAMAGUCHI, Toshiaki, et al.

Appln. No.: Not Yet Assigned

Confirmation No.: Not Yet Assigned

Group Art Unit: Not Yet Assigned

Filed: January 7, 2005 Examiner: Not Yet Assigned

For: PHENOL DERIVATIVES AND METHOD OF USE THEREOF .

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.97 and 1.98

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents is submitted herewith, except for the following: U.S. patents and/or U.S. patent publications; and co-pending non-provisional U.S. applications filed after June 30, 2003.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after

INFORMATION DISCLOSURE STATEMENT

U.S. Appln. No.: Not Yet Assigned

filing a request for continued examination (RCE) under §1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account. A duplicate copy of this paper is attached.

Respectfully submitted,

Registration No. 24,513

Peter D. Olexy

SUGHRUE MION, PLLC

Telephone: (202) 293-7060

Facsimile: (202) 293-7860

WASHINGTON OFFICE 23373
CUSTOMER NUMBER

Date: January 7, 2005

Not Yet Assigne

Not Yet Assigned

January 7, 2005

plete if Known

Substitute for Form 1449 A & B/PTO



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

					First Named Inventor YAMAGUCHI, Toshiaki		
(use as many sheets as necessary)					Art Unit	Not Yet Assigned Not Yet Assigned	
					Examiner Name		
Sheet		1	of	1	Attorney Docket Number	O85464	

Filing Date

Application Number

Confirmation Number

			U.S.	PATENT DOCU	JMENTS
Examiner Initials*	Cite No. ¹	Document N	lumber	Publication Date MM-DD-YYYY	
		Number	Kind Code ² (if known)		Name of Patentee or Applicant of Cited Document
		US 4,226,803		10-07-1980	Klingler et al.
		US 3,278,600		10-11-1966	L'Italien
		US			

FOREIGN PATENT DOCUMENTS							
Examiner	Cite No. ¹	Foreign Patent Document			Publication Date	Name of Patentee or	
Initials*		Country Code ³	Number ⁴	Kind Code ⁵ (if known)	MM-DD-YYYY	Applicant of Cited Document	Translation ⁶
		Japan	137,911		11-01-1975	Sumitomo Chemical Co., Ltd.	No
		UK	2 011 389	A	07-11-1979	Deutsche Gold-und Silber- Scheideanstalt vormals Roessler	English
		BE	660217	Α	08-25-1965	Ciba Ltd.	No
		BE	660218	A	08-25-1965	Ciba Ltd.	No.
						1	
		1		 			

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶		
		CHEMICAL ABSTRACTS; Vol. 69, abs. no. 43560	English		
		CHEMICAL ABSTRACTS, Vol. 63, abs no. 8235a-f	English		
		CAROLL TEMPLE, ET AL.; Antimitotic Agents. Chiral Isomers of Ethyl[5-Amino-1,2-dihydro-3-(4-hydroxyphenyl)-2-methylpyrido[3,4-b]pyrazin-7-yl]carbamate; J. Med. Chem. 1992, 35, 989-993	English		
			<u> </u>		

Examiner Signature	Date Considered	 _

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to indicate here if English language Translation is attached.